Australian pharmaceutical
company Phebra will collaborate
in a new clinical trial to test the
effacy of magnesium sulfate as an
antidote for Irukandji Syndrome
(IS), the acute pain caused by the
stings of certain jellyfish.
Irukandji jellyfish are found across
Australia’s northern waters, from
Exmouth in WA to Moreton Bay in
south-east Queensland, with up
to 60 cases of IS each year causing
symptoms including throbbing pain,
raised blood pressure, breathing
difficulties and headache. Phebra
will be providing the magnesium
sulphate infusions as well as the
placebos to be used in the trial,
which is supported by a grant
from the Queensland Emergency
Medicine Research Foundation.The above article was sent to subscribers in Pharmacy Daily's issue from 08 Dec 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Dec 15
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.